Opendata, web and dolomites

IPUD SIGNED

An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in congestive heart failure patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IPUD project word cloud

Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.

thanks    drains    safety    quality    shock    paragate    renal    infusion    resistant    continuous    healthcare    diuretic    intravenous    aggressive    carry    worsening    urinary    clinical    diuresis    trial    recurrence    treatment    accumulation    24    overload    therapy    heart    prevent    treatments    billion    complications    peritoneal    preventing    health    reduce    validate    efficacy    significantly    global    hospitalizations    catheter    recurred    eliminates    body    million    fluids    verification    pilot    eliminating    frequent    people    guarantees    worldwide    extracellular    ultrafiltration    medical    slowly    monitoring    solutions    sensing    function    severe    laparoscopic    systemic    device    chf    dialysis    life    minimally    platform    physicians    instability    validation    acute    volume    accumulates    absorbs    implantable    hemodynamic    26    metabolic    pump    direct    isotonic    invasive    ipud    removal    pathologic    moderate    perform    patients    congestive    preclinical    water    fluid    chronic    arrhythmia    congestion    patient   

Project "IPUD" data sheet

The following table provides information about the project.

Coordinator
PARAGATE MEDICAL LTD 

Organization address
address: 13 WADI EL HADJ
city: NAZARETH
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙909˙785 €
 EC max contribution 2˙036˙849 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARAGATE MEDICAL LTD IL (NAZARETH) coordinator 2˙036˙849.00

Map

 Project objective

Pathologic fluid overload (congestion) is a medical condition when high volume of fluid (water) accumulates in the body leading to congestive heart failure (CHF). CHF is a severe global health problem affecting each year ~26 million people worldwide, of which 8 million are chronic and diuretic resistant patients. Current solutions for fluid overload in diuretic resistant patients such as infusion pump for intravenous (IV) diuresis, catheter-based device for ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence. Paragate developed IPUD a unique implantable peritoneal ultrafiltration system for continuous monitoring and removal of extracellular fluids in CHF patients. It is minimally invasive (laparoscopic approach) and continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. In addition, IPUD guarantees a continuous monitoring of the fluid as well as the urinary system function thanks to a sensing system (embedded into the implantable system) and a treatment management platform. In this way, physicians have a direct control of the treatment and patient’s condition. The controlled, moderate non-aggressive fluid removal eliminates the main complications associated with the acute and aggressive treatments that lead to hemodynamic shock, worsening of renal function, arrhythmia and metabolic instability. Thanks to IPUD, patients will improve their quality of life eliminating frequent hospitalizations with a more effective treatment and healthcare systems will significantly reduce the €100 billion/year cost for frequent hospitalizations and treatment costs. The Phase 2 project will enable Paragate to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of IPUD in a pilot clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More